Skip to content

ENGNW

enGene Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · CA

$0.17
−0.06%
Ask drillr

Year over year

Reported trailing growth

Revenue
-100.0%
EBITDA
-45.3%
EBIT
+95.4%
EPS
+85.3%
Free cash flow
-9.3%
Operating cash flow
-10.1%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
+33.2%
EPS
—

Three-year CAGR

Revenue
—
EBITDA
—
EBIT
-97.7%
Net income
—
EPS
-56.8%
Free cash flow
—

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jul 1, 2026